The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in ...

The global checkpoint inhibitor refractory cancer market is experiencing significant growth, with an expected valuation of USD 38.69 billion in 2023. This expansion is fueled by the rising health ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Akeso Inc. shares plunged as much as 19% in Hong Kong on Monday morning after preliminary data for its new cancer drug fell ...